Precision Medicine in Dermatology: MEK Inhibition and MAPK Pathway Modulation for Congenital Melanocytic Nevi
Alyssa Forsyth, Ochuwa Precious Imokhai, Kayla Fure, Rafael do Valle, Reem Ayoub, Alejandra Sataray-Rodriguez, Gabriella Martinez, Amanda Brooks · 2026
Read Precision Medicine in Dermatology: MEK Inhibition and MAPK Pathway Modulation for Congenital Melanocytic Nevi by Alyssa Forsyth, Ochuwa Precious Imokhai, Kayla Fure, Rafael do Valle, Reem Ayoub, Alejandra Sataray-Rodriguez, Gabriella Martinez, Amanda Brooks (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13509157.txt.
Description
Alyssa Forsyth and co-authors review in a 2026 article how tailored drugs might treat large moles present from birth. Such moles can turn into skin cancer, and a growth pathway called MAPK drives their growth. Drugs that block one step of that path, the MEK step, are the focus here.
The review weighs lab and clinic proof for these blockers and how they might pair with surgery. Early results look hopeful, yet long-term safety is unproven. Gene tests and marker profiles should guide who gets what, the team argues, so care fits each child's lesion.
Catalog record
| CREATOR | Alyssa Forsyth, Ochuwa Precious Imokhai, Kayla Fure, Rafael do Valle, Reem Ayoub, Alejandra Sataray-Rodriguez, Gabriella Martinez, Amanda Brooks |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |